Vivolution pushes forward PRF (platelet-rich fibrin) system with E7m
This article was originally published in Clinica
Danish automated surgical sealant system developer Vivolution is to ramp up European sales of its Vivostat platelet-rich fibrin (PRF) technology, having secured Euro7m ($9.1m) in its third round of financing. The proceeds will also be used to initiate US clinical studies of the system for FDA approval. The round was led by French VC fund Seventure and Danish private equity firm Vecata. The Vivostat system, which is available widely as a device for the on-site preparation of autologous tissue sealant, has been developed to prepare platelet-rich fibrin for treating chronic wounds.